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Abstract 
Background: Women with previous gestational diabetes mellitus (pGDM) and postpartum normal glucose tolerance 
(NGT) may carry impaired islet β cell secretion, insulin resistance and subsequent altered glucose homeostasis. And 
certain normoglycemic groups at risks of diabetes were presented with elevated glycemic variability. The aim of study 
was to investigate the glycemic variability in NGT women with pGDM.
Methods: Total 48 NGT women with pGDM (pGDM group) and 48 age‑ and BMI‑matched NGT women without 
pGDM (control group) were recruited in the study. Integrated β cell function was assessed with the Insulin Secretion‑
Sensitivity Index‑2 (ISSI‑2) derived from oral glucose tolerance test. All subjects were monitored using the continuous 
glucose monitoring system for consecutive 72 h. The multiple parameters of glycemic variability included the mean 
blood glucose (MBG), standard deviation of blood glucose (SDBG), mean of daily differences (MODD), mean ampli‑
tude of glycemic excursions (MAGE) and the incremental areas above preprandial glucose values (AUCpp).
Results: The pGDM group had a higher MBG (6.5 ± 0.9 vs. 5.9 ± 0.8 mmol/L, p < 0.05), SDBG (1.3 ± 0.3 vs. 
0.9 ± 0.2 mmol/L, p < 0.05), MODD (1.4 ± 0.3 vs. 1.1 ± 0.2 mmol/L, p < 0.05), MAGE (2.7 ± 0.4 vs. 1.8 ± 0.5 mmol/L, 
p < 0.05), and AUCpp (26.8 ± 3.4 vs. 19.2 ± 3.2 mmol/L·h, p < 0.05), when compared to the control group, and the dif‑
ferences remained significant after adjusting for anthropometric indices and metabolic risk factors. Islet β cell function 
index ISSI‑2 in the pGDM group was lower than in the control group (p < 0.05). MBG, SDBG, MODD, MAGE and AUCpp 
were all negatively associated with ISSI‑2 in the pGDM group (r = −0.31, −0.30, −0.34, −0.48 and −0.54, respectively, 
p < 0.05), and the correlations remained significant after adjusting for anthropometric indices and metabolic risk 
factors.
Conclusions: Normal glucose tolerance women with pGDM were presented with elevated glycemic variability, 
which may be associated with impaired islet β cell function.
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Background
Gestational diabetes mellitus (GDM) was associated with 
increased risks of developing postpartum pre-diabe-
tes, type 2 diabetes and metabolic syndrome [1, 2]. The 
relationships reflected the fact that GDM and type 2 dia-
betes shared a similar pathophysiology, characterized by 
deficiency in islet β cell secretion and insulin sensitivity 
[3, 4]. GDM may serve as a window to reveal a predispo-
sition to type 2 diabetes.
It also had been repeatedly demonstrated that women 
with previous GDM (pGDM) and even with postpar-
tum normal glucose tolerance (NGT) carried deficiency 
in islet β cell secretion and insulin sensitivity and sub-
sequent altered glucose homeostasis [5–7]. Definition 
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of NGT was based on fasting plasma glucose (FPG) 
<5.6  mmol/L and 2-h postload plasma glucose (2hPG) 
<7.8  mmol/L during a 75-g oral glucose tolerance test 
(OGTT) [8]. Detection of glucose values at 0 and 120 min 
by OGTT may miss the potential glycemic variability. 
And previous studies conducted in NGT subjects at risks 
of developing diabetes showed that glycemic excursions 
were in the range of prediabetes as well as the diabetes 
[9, 10]. So we hypothesized that women with pGDM 
and even with NGT status may have altered glycemic 
variability.
Efforts to quantify glycemic variability mainly relied 
on intermittent glucose determinations which acquired 
from the continuous glucose monitoring (CGM) system 
(CGMS), and CGM system can detect glycemic variabil-
ity in more details than the conventional self-monitoring 
methods of blood glucose [11, 12]. Glycemic variability 
parameters estimated by the multiple modalities of CGM 
data [13] may differ in NGT women with and without the 
pGDM.
The present study was designed to investigate the gly-
cemic variability assessed by CGM in postpartum NGT 
women with the pGDM.
Methods
Study subjects
This cross-sectional study was performed at outpatient 
and inpatient department of the Second Affiliated Hos-
pital of Nantong University in China from January 2010 
to May 2014. Total 502 women who had the diagnosis 
of GDM between 24 and 28th week of pregnancy were 
revisited and screened by 75-g oral glucose tolerance test 
(OGTT) after delivery for 1  year. And 48 women, who 
detected with postpartum NGT and agreed to be per-
formed with CGM, were recruited for the further study 
(pGDM group). The diagnoses of NGT and GDM were 
based on the criteria of the ADA 2008 [8]. NGT was 
defined as FPG <5.6  mmol/L and 2hPG <7.8  mmol/L 
during the OGTT. GDM was made when two of the 
following plasma glucose values in the 75-g OGTT 
are exceeded: fasting, 5.3  mmol/L; 1  h, 10.0  mmol/L; 
2  h, 8.6  mmol/L. Meanwhile, 48 healthy women with-
out pGDM, who selected and diagnosed with NGT 
after delivery for 1  year in the same department, were 
recruited and set as controls in the study (control group). 
The two groups were also matched for age and body 
mass index (BMI). And exclusion criteria for control 
group were as follows: family history of diabetes, lipid 
abnormalities, hypertension, hepatic disease, chronic 
kidney disease, cardiovascular disease, malignancy, or 
other disorders affecting glucose metabolism such as 
hyperthyroidism. The study was approved by the institu-
tional review board of the Second Affiliated Hospital of 
Nantong University, with written informed consent being 
obtained from all participants.
β cell function determination
Blood samples were taken at 0, 30, 60, 120 and 180 min 
for the measurement of plasma glucose and insulin con-
centrations (glucose unit: mmol/L, insulin unit: miu/L) 
during 75-g oral glucose test. Glut and Inst represent 
the plasma glucose and insulin concentrations, respec-
tively, at time t during the OGTT. Insulin sensitivity 
was estimated using the insulin sensitivity index (ISI) 
of Matsuda and DeFronzo: ISI =  10,000/square root of 
(Ins0 ×  Glu0) ×  (mean glucose ×  mean insulin during 
OGTT) [14]. Insulin secretion was defined as the ratio of 
the area-under-the-insulin-curve to the area-under-the-
glucose curve (AUCins/glu) [15, 16]. Integrated β cell func-
tion was assessed with the Insulin Secretion-Sensitivity 
Index-2 (ISSI-2) (AUCins/glu multiplied by ISI) [16, 17].
CGM in all subjects
After OGTT, all subjects were monitored by CGMS 
(Medtronic MiniMed, Northridge, CA 91325, USA) for 
72 h. The CGM system sensor was inserted in all subjects 
on day 0 and removed on day 3. Data were downloaded 
and glucose profiles were evaluated based on the data 
collected on days 1 and 2. The subjects were instructed 
to input at least four calibration readings per day and the 
times of key events. During the study, all subjects have 
standard meals provided by dietary division. The total 
calorie intake was 30  kcal/kg per day, with 50  % carbo-
hydrates, 15 % proteins, and 35 % fats. The calorie distri-
bution between breakfast, lunch, and dinner was 20, 40, 
and 40 %, respectively. Three daily meals were required to 
consume at time of 6:30–7:30, 11:30–12:30, and 18:00–
19:00, respectively. All subjects were instructed to avoid 
strenuous exercise during CGM.
The parameters of glycemic variability included the 
standard deviation of blood glucose (SDBG), mean of 
daily continuous 24  h blood glucose (MBG), mean of 
daily differences (MODD), mean amplitude of glycemic 
excursions (MAGE) and the incremental areas above pre-
prandial glucose values (AUCpp). MODD was calculated 
from the absolute difference between paired continuous 
glucose monitoring values during two successive 24  h 
periods and was used to assess inter-day glycemic vari-
ability [18]. MAGE, designed to quantify major swings 
of glycemia and to exclude minor ones, was used for 
assessing intra-day glycemic variability in this study [19]. 
AUCpp, calculated incremental areas of glucose above the 
each meal, was performed to evaluate the characteristics 
of postprandial glucose excursion [20]. It should be noted 
that MBG was a measure of overall of glycemic level and 
not specifically variability [21].
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Anthropometric indices and laboratory examination
Body mass index (BMI) was calculated (kg/m2). Systolic 
blood pressure (SBP) and diastolic blood pressure (DBP) 
taken three times using a sphygmomanometer and then 
averaged. Capillary glucose concentrations were meas-
ured with Lifescan Surestep blood glucose meter. Plasma 
glucose levels were measured using the glucose oxidase 
method. HbA1c was measured by high performance 
liquid chromatography (HPLC) with D-10 hemoglobin 
Testing Program (Bio-Rad). The serum insulin assay used 
magnetic beads-based enzymatic spectrofluoromet-
ric immunoassay with automatic enzyme immunoassay 
apparatus (AIA360, TOSOH). Serum glucose concen-
trations, total cholesterol (TC), triglyceride (TG), high 
density lipoprotein cholesterol (HDLC), and low den-
sity lipoprotein cholesterol (LDLC) were measured with 
Hitachi Model 7600 Series Automatic Analyzer.
Statistical analyses
Data analyses were performed using the SPSS16.0 sta-
tistical software (SPSS Inc., USA). Continuous variables 
were expressed as mean  ±  standard deviation (SD) or 
median (interquartile range) in the case of skewed dis-
tributions. Categorical variables were described as fre-
quency (percentage). The Student t test was applied to 
compare differences of continuous variables between the 
pGDM and control groups, nonparametric test (Mann–
Whitney U test) was applied to compare non-normally 
distributed variables between the two groups, and Chi 
squared test was applied to compare categorical variables 
between the two groups. Relationship between glycemic 
variability and integrated β cell function was assessed 
using the Pearson’s correlation test and partial correlation 
test. p < 0.05 was considered to be statistically significant.
Results
Baseline characteristics in the subjects
As shown in Table 1, age, BMI and DBP were comparable 
between the pGDM and control groups (p  >  0.05). SBP 
of pGDM group was higher than that in control group 
(p < 0.05). The prevalence of familial diabetes of pGDM 
group was higher than in control group (p  <  0.05). TC, 
LDLC of pGDM group were higher than in control group 
(p  <  0.05), HDLC of pGDM group was lower than in 
control group (p < 0.05), but there was no differences in 
TG between the two groups (p > 0.05). HbA1c of pGDM 
group was higher than that in control group (p < 0.05).
Changes of plasma glucose and insulin concentrations 
during the OGTT, and β cell functions derived from OGTT
The statistical comparisons of measurements charac-
terizing the plasma glucose and insulin concentrations 
during the OGTT were summarized in Table  2. Plasma 
glucose levels at baseline, 30, 60 and 120 min after glu-
cose ingestion were higher in pGDM group was higher 
than that in control group (p < 0.05), plasma glucose level 
at 180  min had no significantly difference between the 
two groups (p  >  0.05). Insulin concentration at 60  min 
was significantly higher in pGDM group than in control 
group (p < 0.05), but there were no differences in insulin 
concentrations at baseline, 30, 120 and 180 min between 
the two groups (p  >  0.05). The area under the glucose 
curve (AUCglu) was significantly higher in pGDM group 
than in control group (p < 0.05), but the area under the 
insulin curve (AUCins) was comparable between the 
pGDM and control groups (p > 0.05).
After comparison of insulin sensitivity and insulin 
secretion index derived from OGTT, insulin sensitivity 
index (Matsuda ISI) and insulin secretion index (AUCins/
glu) in pGDM group were lower than in control group 
(p  <  0.05) (Table  2). Integrated β cell function (ISSI-2) 
was significantly lower in pGDM group than in control 
group (p < 0.01).
Glycemic variability in the subjects
Glycemic variability detected from CGM system of 
pGDM and control groups were represented in Fig.  1. 
Although both pGDM and control groups were pre-
sented with NGT, the pGDM group had a greater MBG 
(6.5  ±  0.9 vs. 5.9  ±  0.8  mmol/L, p  =  0.004), SDBG 
(1.3  ±  0.3 vs. 0.9  ±  0.2  mmol/L, p  =  0.000), MODD 
(1.4  ±  0.3 vs. 1.1  ±  0.2  mmol/L, p  =  0.002), MAGE 
Table 1 Comparisons of  clinical variables in  pGDM 
and control groups
Normally distributed values in the table are given as the mean ± SD, the non-
normally distributed values are given as the median (25 and 75 % interquartiles)
pGDM group: NGT women with the previous GDM; Control group: NGT women 
without the previous GDM
BMI body mass index, SBP/DBP systolic/diastolic blood pressure, TC total 
cholesterol; TG triglyceride, HDLC: high density lipoprotein cholesterol, LDLC low 
density lipoprotein cholesterol, HbA1c glycosylated hemoglobin A1c
* Test with Fisher’s Exact test; ** Test with Mann–Whitney U test
Variables pGDM group Control group t p
n 48 48 – –
Age (year) 29.1 ± 4.1 29.8 ± 3.6 0.941 0.349
Familial diabetes, n (%) 7 (14.6) 0 (0.0) – 0.012*
BMI (kg/m2) 26.8 ± 3.2 26.3 ± 2.9 0.768 0.444
SBP (mmHg) 130 ± 13 119 ± 15 3.502 0.001
DBP (mmHg) 76 ± 9 75 ± 10 0.493 0.623
TG (mmol/L) 1.5 (1.2–2.0) 1.3 (1.2–1.8) – 0.442**
TC (mmol/L) 6.2 ± 1.0 4.8 ± 0.8 8.320 0.000
HDLC (mmol/L) 1.1 ± 0.3 1.3 ± 0.3 2.265 0.026
LDLC (mmol/L) 3.3 ± 0.9 2.4 ± 0.5 6.588 0.000
HbA1c (%) 5.8 ± 0.4 5.4 ± 0.3 8.617 0.000
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(2.7 ± 0.4 vs. 1.8 ± 0.5 mmol/L, p = 0.000), and AUCpp 
(26.8 ±  3.4 vs. 19.2 ±  3.2  mmol/L·h, p =  0.000), when 
compared to the control group (Table 3). And the differ-
ences remained significant after adjusting for age, familial 
diabetes, BMI, SBP, DBP, TG, TC, HDLC and LDLC.
Relationships between glycemic variability and ISSI‑2 
in pGDM group
When the relationships between glycemic variabil-
ity parameters and ISSI-2 were analyzed by Pearson’s 
correlation test, MBG (r  =  –0.31, p  =  0.028), SDBG 
(r = −0.30, p = 0.037), MODD (r = −0.34, p = 0.017), 
MAGE (r = −0.48, p =  0.000) and AUCpp (r = −0.54, 
p = 0.000) of pGDM group were all negatively associated 
with ISSI-2 in pGDM group (Fig. 2a–e). And the correla-
tions remained significant after adjusting for age, familial 
diabetes, BMI, SBP, DBP, TG, TC, HDLC and LDLC.
Discussion
In the specific group of pGDM women, our present study 
found that these women even with postpartum NGT 
were presented with elevated glycemic variability param-
eters. CGM can provide additional glycemic information 
compared to OGTT. Detailed 24 h glycemic profiles can 
be documented by CGM. Certain groups at high risks of 
diabetes, with so-called NGT status based on the OGTT, 
were presented with elevated glycemic variability. The 
study by Ma et al. [22] demonstrated that glycemic varia-
bility was increased in abdominally obese men with NGT. 
A study conducted in cystic fibrosis patients, it had been 
observed that normoglycemic subjects by OGTT had 
glucose excursions in the prediabetes as well as the dia-
betes range [9]. Madhu et al. [10] showed the normogly-
cemic obese first-degree relatives of type 2 diabetes had 
excursions into the higher dysglycemic range when stud-
ied by CGMS, and 90 % of subjects had excursions into 
the IGT range, and 15 % had excursions into the diabetes 
range. A1c-Derived Average Glucose (ADAG) study [23] 
showed 93 % of non-diabetic subjects exceeded the IGT 
threshold of 7.8  mmol/L, 7  % of them reached diabetes 
threshold of 11.1  mmol/L during CGMS, and the mean 
HbA1c in these subjects was within the normal range 
Table 2 Comparisons of  glucose and  insulin concentra-
tions during OGTT in pGDM and control groups
Non-normally distributed values are given as the median (25 and 75 % 
interquartiles)
pGDM group: NGT women with the previous GDM; Control group: NGT women 
without the previous GDM
Glut plasma glucose concentrations at time t during OGTT, Inst plasma insulin 
concentrations at time t during OGTT, AUCglu the area under the curve of glucose 
in 180 min, AUCins the area under the curve of insulin in 180 min, ISI insulin 
sensitivity index, AUCins/glu insulin secretion index, ISSI-2 insulin secretion-
sensitivity index-2
* Test with Mann–Whitney U test
Variables pGDM group Control group t p
n 48 48 – –
Glu0 (mmol/L) 5.5 ± 0.6 5.1 ± 0.5 3.845 0.000
Glu30 (mmol/L) 9.0 ± 1.7 7.5 ± 1.4 4.771 0.000
Glu60 (mmol/L) 8.8 ± 2.8 6.7 ± 2.3 4.071 0.000
Glu120 (mmol/L) 6.0 ± 1.1 5.4 ± 1.4 2.722 0.008
Glu180 (mmol/L) 4.9 ± 1.0 4.8 ± 1.0 0.677 0.500
Ins0 (miu/L) 6.3 (3.9–9.7) 5.6 (4.0–7.8) – 0.391*
Ins30 (miu/L) 54.6 (36.4–88.7) 56.1 (37.9–77.0) – 0.800*
Ins60 (miu/L) 63.1 (40.9–85.0) 44.1 (28.5–65.4) – 0.011*
Ins120 (miu/L) 31.3 (14.9–42.6) 28.5 (21.6–40.1) – 0.823*
Ins180 (miu/L) 9.2 (5.5–13.6) 8.1 (4.7–17.2) – 0.496*
AUCglu  
(mmol/L·h)
18.4 ± 2.8 15.7 ± 2.5 4.712 0.000
AUCins (miu/L·h) 114.7 (74.17–
163.8)
99.6 (75.2–132.1) – 0.356*











Fig. 1 Continuous glucose profiles represented mean data from 24 h 
in pGDM and control groups
Table 3 Comparisons of  glycemic variability parameters 
in pGDM and control groups
Normally distributed values in the table are given as the mean ± SD
pGDM group: NGT women with the previous GDM; Control group: NGT women 
without the previous GDM
MBG mean of blood glucose, SDBG standard deviation of blood glucose, MODD 
mean of daily differences, MAGE mean amplitude of glycemic excursions, AUCpp 
incremental areas above preprandial glucose values
Variables pGDM group Control group t p
n 48 48 – –
MBG (mmol/L) 6.5 ± 0.9 5.9 ± 0.8 2.967 0.004
SDBG (mmol/L) 1.3 ± 0.3 0.9 ± 0.2 6.169 0.000
MODD (mmol/L) 1.4 ± 0.3 1.1 ± 0.2 3.186 0.002
MAGE (mmol/L) 2.7 ± 0.4 1.8 ± 0.5 8.696 0.000
AUCpp (mmol/L·h) 26.8 ± 3.4 19.2 ± 3.2 11.267 0.000
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Fig. 2 The relationships between glycemic variability parameters (a MBG, b SDBG, c MODD, d MAGE, e AUCpp) and ISSI‑2 in pGDM and control 
groups
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according to the ADA recommendations. Our previous 
study also showed that glycemic variability in normogly-
cemic subjects with elevated 1-h postload plasma glu-
cose levels (NGT 1  h ≥  8.6  mmol/L group) was higher 
than those in NGT 1 h < 8.6 mmol/L group [24]. Women 
with pGDM, and with postpartum NGT classified by the 
OGTT, had increased glycemic variability compared to 
NGT ones without pGDM in the present study. Glycemic 
variability parameters SDBG, MBG, MODD, MAGE and 
AUCpp were elevated in women with pGDM. Our finding 
demonstrated the characteristics of glycemic variability 
in NGT women with pGDM.
The pGDM identified a population of young women 
predisposed for type 2 diabetes and related cardiovascu-
lar disease. Retnakaran et al. [25, 26] showed any degree 
of abnormal glucose homeostasis detected on antepar-
tum screening for GDM should be associated with an 
increased risk of postpartum pre-diabetes, diabetes and 
latent metabolic syndrome. Elevated circulating markers 
of endothelial dysfunction in young women with a his-
tory of GDM could reflect an early stage on the pathway 
to the manifestation of future cardiometabolic disor-
ders [27]. And Bo et al. [28] showed women with previ-
ous GDM have been shown to express early markers of 
vascular dysfunction such as increased intima-media 
thickness of carotid arteries(C-IMT). Zajdenverg et  al. 
[29] showed microcirculation abnormality, evaluated by 
papillae rectification, was carried in young non-diabetic 
women with pGDM. Our study showed the normogly-
cemic women with pGDM were presented with elevated 
glycemic variability parameters, when compared with the 
women without pGDM. And elevated glycemic variabil-
ity could be considered as a marker of metabolic abnor-
mality of pGDM.
Glycemic variability could be an independent risk fac-
tor for vascular complications in addition to average glu-
cose [30, 31]. Glucose variability parameters could be 
calculated with complex formulas designed specifically 
for the CGM data. In the previous studies, the SDBG 
around the mean glucose value was considered as a clas-
sical index to assess the glycemic variability [32]. MODD 
and MAGE are objective and valid indices to measure 
inter-day and intra-day glucose variability, respectively 
[18, 19]. AUCpp was performed to evaluate the char-
acteristics of postprandial glucose excursion [20]. And 
several studies had demonstrated that glycemic vari-
ability, assessed by MAGE, was closely associated with 
micro- and macro-vascular complications [33, 34]. Our 
presented study demonstrated that glycemic variability 
parameters SDBG, MBG, MODD, MAGE and AUCpp 
in pGDM group were higher than in the control group. 
Women with pGDM carried with early markers of vascu-
lar dysfunction [28, 29]. Hence, it implies that glycemic 
variability may be related to early markers of vascular 
dysfunction in women with pGDM. But it needs further 
study to document whether glycemic variability remis-
sion can improve the markers of vascular dysfunction in 
pGDM group.
GDM and type 2 diabetes shared a similar pathophysi-
ology, characterized by deficiency in islet β cell secretion 
and insulin sensitivity, and GDM was a stress situation 
that may reveal predisposition to type 2 diabetes. Previ-
ous studies had shown that women with previous GDM 
even with postpartum normal oral glucose tolerance test 
had both insulin secretion and action defects [5, 6]. And 
our study showed insulin secretion and insulin sensitiv-
ity indices derived from OGTT were decreased in pGDM 
group than in control group. ISSI-2 proposed by Retna-
karan et al. [16, 17] was a composite measure and may be 
a better index than either AUCins/glu or ISI alone to reflect 
the notion of declining β cell function and account for 
glycemic disorders. After correlation analyzing, SDBG, 
MBG, MODD, MAGE, and AUCpp all negatively asso-
ciated with the ISSI-2 in pGDM group. The decreased 
ISSI-2 of pGDM may be responsible for elevated glyce-
mic variability.
It should be pointed out that our study had some limi-
tations. First, the family history of diabetes could exag-
gerate the difference of glycemic variability between 
NGT women with and without previous GDM, but 
the comparison of glycemic variability between the 
two groups was adjusted for the familial diabetes. The 
pGDM group should be theoretically divided into sub-
groups with and without familial diabetes for further 
comparison, but the small sample size of subgroups 
might make some differences insignificant. Second, 
although we provided standard meals for subjects dur-
ing the CGM system monitoring period, some factors, 
such as physical activity and emotional stress, etc., 
which may affect levels of glycemic variability, could not 
all be prevented. Third, we could not assess glycemic 
variability in relation to oxidative stress, inflammation 
and other markers of vascular dysfunction. The fourth 
limitation related to ISSI-2 was that circulating insulin 
levels during the OGTT may be affected by other fac-
tors apart from β cell function, such as incretin hor-
mones and hepatic extraction. The two factors may limit 
the degree to which insulin levels during the OGTT can 
reflect β cell function.
Conclusions
In summary, the glycemic variability parameters in NGT 
women with pGDM were higher than those in the NGT 
ones without pGDM, and elevated glycemic variabil-
ity parameters may be associated with impaired β cell 
function.
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